Size | Price | Stock | Qty |
---|---|---|---|
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
Rifamycin·Na (Rifamycin SV monosodium; Rifocin; Rifamastene; CB 01-11, NSC-146718) is naturally occurring and broad-spectrum antibiotic acting as an inhibitor of bacterial DNA-dependent RNA polymerase, which may lead to the suppression of RNA synthesis and cell death. It is effective against Gram-positive bacteria and is moderately active against Gram-negative bacteria.
Molecular Formula |
C37H46NNAO12
|
---|---|
Molecular Weight |
719.8
|
Exact Mass |
719.29177018
|
CAS # |
14897-39-3
|
Related CAS # |
Rifamycin; 6998-60-3
|
Appearance |
Light brown to brown solid
|
SMILES |
C[C@H]1/C=C/C=C(\C(=O)NC2=CC(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)[O-])/C.[Na+]
|
InChi Key |
YVOFSHPIJOYKSH-NLYBMVFSSA-M
|
InChi Code |
InChI=1S/C37H47NO12.Na/c1-16-11-10-12-17(2)36(46)38-23-15-24(40)26-27(32(23)44)31(43)21(6)34-28(26)35(45)37(8,50-34)48-14-13-25(47-9)18(3)33(49-22(7)39)20(5)30(42)19(4)29(16)41;/h10-16,18-20,25,29-30,33,40-44H,1-9H3,(H,38,46);/q;+1/p-1/b11-10+,14-13+,17-12-;/t16-,18+,19+,20+,25-,29-,30+,33+,37-;/m0./s1
|
Chemical Name |
sodium;(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-13-acetyloxy-2,15,17,29-tetrahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-27-olate
|
Synonyms |
Rifamycin SV monosodiumRifocin RifamasteneCB-0111, NSC146718 CB 01-11, NSC-146718
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~250 mg/mL (~347.34 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (2.89 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (2.89 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.3893 mL | 6.9464 mL | 13.8927 mL | |
5 mM | 0.2779 mL | 1.3893 mL | 2.7785 mL | |
10 mM | 0.1389 mL | 0.6946 mL | 1.3893 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04349579 | Active recruiting |
Drug: Rifamycine Drug: Saline Solution |
Impacted Third Molar Tooth | Yuzuncu Yıl University | November 15, 2018 | Phase 4 |
NCT03345823 | Active recruiting |
Drug: Upadacitinib Drug: Placebo for Upadacitinib |
Crohn's Disease | AbbVie | March 21, 2018 | Phase 3 |
NCT04026984 | Not yet recruiting | Drug: Rifamycin SV-MMX Drug: Placebo |
Traveler's Diarrhea | RedHill Biopharma Limited | June 2024 | Phase 2 |
NCT04027894 | Not yet recruiting | Drug: Rifamycin SV MMX Drug: Placebo to Rifamycin SV-MMX |
Traveler's Diarrhea | RedHill Biopharma Limited | January 2024 | Phase 2 |
NCT05588492 | Recruiting | Drug: Rifamycin-free regimen Drug: Rifamycin-containing regimen |
Pulmonology | National Taiwan University Hospital |
January 1, 2022 | Phase 4 |